Papers/PMID:37338608
The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.
Archives of osteoporosis2023The record
2 findings · 1 compound · 2 endpoints · 2 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
phylloquinone — no detected effect on femoral neck bone mineral density
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”
Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.. - Study
- RCT
- Dose
- 1 mg/day vitamin K1
- Population
- Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.2023PMID:37338608Permalink
phylloquinone — no detected effect on lumbar spine bone mineral density
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”
Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.. - Study
- RCT
- Dose
- 1 mg/day vitamin K1
- Population
- Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.2023PMID:37338608Permalink